Annovis Bio Inc (ANVS) - Total Assets
Based on the latest financial reports, Annovis Bio Inc (ANVS) holds total assets worth $17.19 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See ANVS total equity for net asset value and shareholders' equity analysis.
Annovis Bio Inc - Total Assets Trend (2009–2024)
This chart illustrates how Annovis Bio Inc's total assets have evolved over time, based on quarterly financial data.
Annovis Bio Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Annovis Bio Inc's total assets of $17.19 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 75.8% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2009–2024)
This chart illustrates how Annovis Bio Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Annovis Bio Inc stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Annovis Bio Inc's current assets represent 100.0% of total assets in 2024, an increase from 8.0% in 2009.
- Cash Position: Cash and equivalents constituted 75.8% of total assets in 2024, up from 2.1% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 90.0% in 2009.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Annovis Bio Inc Competitors by Total Assets
Key competitors of Annovis Bio Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Ascendis Pharma AS
F:A71
|
Germany | €1.30 Billion |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥6.69 Billion |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333
|
China | CN¥2.31 Billion |
|
Shanghai Shen Lian Biomedical Corp
SHG:688098
|
China | CN¥1.56 Billion |
Annovis Bio Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.60 | 2.66 | 14.04 |
| Quick Ratio | 4.60 | 2.66 | 14.04 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $13.46 Million | $8.97 Million | $7.54 Million |
Annovis Bio Inc - Advanced Valuation Insights
This section examines the relationship between Annovis Bio Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.77 |
| Latest Market Cap to Assets Ratio | 4.26 |
| Asset Growth Rate (YoY) | 36.4% |
| Total Assets | $13.93 Million |
| Market Capitalization | $59.28 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Annovis Bio Inc's assets at a significant premium (4.26x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Annovis Bio Inc's assets grew by 36.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Annovis Bio Inc (2009–2024)
The table below shows the annual total assets of Annovis Bio Inc from 2009 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $13.93 Million | +36.42% |
| 2023-12-31 | $10.21 Million | -71.66% |
| 2022-12-31 | $36.02 Million | -21.69% |
| 2021-12-31 | $46.00 Million | +466.57% |
| 2020-12-31 | $8.12 Million | +626.82% |
| 2019-12-31 | $1.12 Million | +2090.75% |
| 2018-12-31 | $50.99K | -85.75% |
| 2017-12-31 | $357.96K | -87.37% |
| 2012-12-31 | $2.84 Million | -86.51% |
| 2011-12-31 | $21.01 Million | -4.68% |
| 2010-12-31 | $22.05 Million | +1348.62% |
| 2009-12-31 | $1.52 Million | -- |
About Annovis Bio Inc
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 2/3 to treat alzheimer's disease, as well as in phase 3 to treat parkinson's disease; and is in phase 2 clinical trial to treat lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinic… Read more